Literature DB >> 24727060

A new adjuvant delivery system 'cyclic di-GMP/YSK05 liposome' for cancer immunotherapy.

Hiroko Miyabe1, Mamoru Hyodo2, Takashi Nakamura1, Yusuke Sato1, Yoshihiro Hayakawa3, Hideyoshi Harashima4.   

Abstract

Cyclic dinucleotides are of importance in the field of microbiology and immunology. They function as second messengers and are thought to participate in the signal transduction of cytosolic DNA immune responses. One such dinucleotide, cyclic di-GMP (c-di-GMP), stimulates the immune system. It is thought that c-di-GMP is recognized by ATP dependent RNA helicase (DDX41) in the cytosol, forms a complex with the Stimulator of interferon genes protein (STING), triggers a signal via the tank binding kinase 1-interferon regulatory factor 3 (TBK1-IRF3) pathway and induces the production of type I interferons. Therefore c-di-GMP can be thought of as a new class of adjuvant. However, because c-di-GMP contains two phosphate groups, this prevents its use as an adjuvant because it cannot pass through the cell membrane, even though the target molecule of c-di-GMP is located in the cytoplasm. Our group has been developing a series of liposomal drug delivery systems and recently investigated YSK05 which is a synthetic, pH sensitive lipid that has a high fusogenicity. We utilized this lipid as a carrier to transport c-di-GMP into the cytosol to then use c-di-GMP as an adjuvant. Based on screening experiments, YSK05/POPE/cholesterol=40/25/35 was found to induce IFN-β in Raw264.7 cells. The induction of IFN-β from c-di-GMP liposomes was inhibited by adding BX795, a TBK1 inhibitor, indicating that the production of IFN-β caused the activation of the STING-TBK1 pathway. C-di-GMP liposomes also showed significantly higher levels of expression of CD80, CD86 and MHC class I. The c-di-GMP/YSK05 liposome facilitated antigen specific cytotoxic T cell activity and the inhibition of tumor growth in a mouse model. These findings indicate that c-di-GMP/YSK05 liposomes could be used, not only to transfer c-di-GMP to the cytosol and induce an innate immune system but also as a platform for investigating the mechanism of immune sensing with cyclic dinucleotides in vitro and in vivo.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adjuvant; Anti-tumor activity; C-di-GMP; Liposome

Mesh:

Substances:

Year:  2014        PMID: 24727060     DOI: 10.1016/j.jconrel.2014.04.004

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  37 in total

Review 1.  Nanoparticle systems for cancer vaccine.

Authors:  Ru Wen; Afoma C Umeano; Yi Kou; Jian Xu; Ammad Ahmad Farooqi
Journal:  Nanomedicine (Lond)       Date:  2019-02-26       Impact factor: 5.307

2.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Authors:  Melissa C Hanson; Monica P Crespo; Wuhbet Abraham; Kelly D Moynihan; Gregory L Szeto; Stephanie H Chen; Mariane B Melo; Stefanie Mueller; Darrell J Irvine
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

3.  Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy.

Authors:  Naihan Chen; Matthew D Gallovic; Pamela Tiet; Jenny P-Y Ting; Kristy M Ainslie; Eric M Bachelder
Journal:  J Control Release       Date:  2018-09-24       Impact factor: 9.776

4.  A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.

Authors:  Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Michael A Collier; Rebekah Watkins-Schulz; Ning Cheng; Clément N David; Charles E McGee; Gregory D Sempowski; Ivo Shterev; Karen McKinnon; Eric M Bachelder; Kristy M Ainslie; Jenny P-Y Ting
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

Review 5.  Synthetic nanovaccines for immunotherapy.

Authors:  Min Luo; Layla Z Samandi; Zhaohui Wang; Zhijian J Chen; Jinming Gao
Journal:  J Control Release       Date:  2017-03-21       Impact factor: 9.776

6.  Stimulation of innate immunity by in vivo cyclic di-GMP synthesis using adenovirus.

Authors:  Benjamin J Koestler; Sergey S Seregin; David P W Rastall; Yasser A Aldhamen; Sarah Godbehere; Andrea Amalfitano; Christopher M Waters
Journal:  Clin Vaccine Immunol       Date:  2014-09-17

Review 7.  Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Authors:  Samaresh Sau; Hashem O Alsaab; Ketki Bhise; Rami Alzhrani; Ghazal Nabil; Arun K Iyer
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

8.  Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.

Authors:  Michael A Collier; Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Monica M Johnson; Andrew N Macintyre; Gregory D Sempowski; Eric M Bachelder; Jenny P-Y Ting; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2018-10-15       Impact factor: 4.939

9.  In Vivo Synthesis of Cyclic-di-GMP Using a Recombinant Adenovirus Preferentially Improves Adaptive Immune Responses against Extracellular Antigens.

Authors:  Fadel S Alyaqoub; Yasser A Aldhamen; Benjamin J Koestler; Eric L Bruger; Sergey S Seregin; Cristiane Pereira-Hicks; Sarah Godbehere; Christopher M Waters; Andrea Amalfitano
Journal:  J Immunol       Date:  2016-01-20       Impact factor: 5.422

10.  Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy.

Authors:  Sandeep T Koshy; Alexander S Cheung; Luo Gu; Amanda R Graveline; David J Mooney
Journal:  Adv Biosyst       Date:  2017-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.